Best Cardiac and Vascular Disorders Companies in United Kingdom
The 92 best Cardiac and Vascular Disorders companies in United Kingdom in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Verdiva Bio.
Ranked by disclosed equity funding and recent momentum, the Cardiac and Vascular Disorders companies in United Kingdom tracked here represent a sector that's quieter on unicorns than you might expect but loud on capital concentration. Ninety-two companies. $1.1 billion in total disclosed funding. No unicorns. And the spread tells the real story: Verdiva Bio sits at $411 million, Mission Therapeutics at $179 million, while most of the remaining field is working with single-digit millions or less.
That gap matters. SignaCor has disclosed under $340,000. Echopoint Medical, $10 million. So when I look at this directory, what strikes me isn't the headline total, it's how few names are carrying the weight. Investors like Deepbridge Capital and Innovate UK are active across the pack, but concentration is real. Coverage momentum is flat right now, with research attention drifting toward valve replacement surgery, non-HDL cholesterol markers, and age-related disease mechanisms rather than any single breakout company. If you're trying to place this sector, think steady capital accumulation with a narrow elite, not a broad rising tide.
Ranked: Best Cardiac and Vascular Disorders companies in United Kingdom
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Verdiva Bio Developer of oral and injectable peptide therapies for metabolic diseases 50Funding top 21%Moat top 40%Market bottom 49%Talent bottom 49% All 5 signals ▾Fundingtop 21% Moattop 40% Marketbottom 49% Talentbottom 49% Globalbottom 45% Funding: Raised $411M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Moat: Soonicorn · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 50/100 | $411M | 17 mo ago | — | Khurem Farooq Co-Founder & CEO | Series A | — | — |
| 2 | Mission Therapeutics Developer of small molecule inhibitors targeting specific disease associated enzymes 53Funding top 26%Moat top 26%Patents top 29%Innovation top 35% All 10 signals ▾Fundingtop 26% Moattop 26% Patentstop 29% Innovationtop 35% Talenttop 38% Growthtop 48% Markettop 50% Globalbottom 42% Fin. healthbottom 31% Newsbottom 21% Funding: Raised $179M across 9 rounds · 9 rounds over 15 yrs (0.6/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 305 patents rank vs industry peers · Fliar Intelligence Index 53/100 | $179M | 8 mo ago | 45 | Keith Menear Co-Founder | Series D | 305 patents Small-molecule USP30 deubiquitinase inhibitors for mitochondrial disease, cancer, and fibrosis | — |
| 3 | Ixaka Developer of cell-based therapeutic solutions for the treatment of multiple therapeutic conditions | $54M | 65 mo ago | 9 | Vicente Gonzalez Co-Founder | Deadpooled | — | — |
| 4 | Sky Medical Technology Electro stimulation devices for treatment of Deep vein thrombosis | $49M | 75 mo ago | 32 | Bernard Ross CEO and Founder | Series B | 92 patents Microcirculation enhancement devices for ischemia treatment and neuromuscular stimulation | 1 launch |
| 5 | Veryan Medical 3D stent for peripheral vascular disease | $41M | 137 mo ago | 35 | Professor Colin Caro | Series B | 103 patents Intravascular balloon catheters and stent delivery systems for minimally invasive procedures. | 1 launch |
| 6 | Intervene Medical device company that develops catheter based therapy for chronic venous insufficieny (CVI) | $38M | 20 mo ago | 11 11 → 18 (+64%) | Iden Shams Executive Director | Series B | — | — |
| 7 | Neograft Technologies Sleeve to strengthen grafted veins | $37M | 112 mo ago | 3 | — | Deadpooled | — | — |
| 8 | Vivacta Platform for point of care testing | $30M | 188 mo ago | 11 | — | Deadpooled | 113 patents Optical and piezoelectric sensor technologies for chemical analyte detection | — |
| 9 | Morphogen-IX Provider of therapeutics for pulmonary arterial hypertension (PAH) | $25M | 90 mo ago | 1 | — | Series B | — | — |
| 10 | Calon Cardio-Technology Developer of implantable heart pumps for heart failure treatment | $24M | 52 mo ago | 21 | Stephen Westaby Co-Founder & Director | Series B | 66 patents Implantable cardiac assist devices and ventricular pump systems for circulatory support. | — |
| 11 | Heart Metabolics Pharmaceutical therapy for the treatment of hypertrophic cardiomyopathy (“HCM”). | $24M | 146 mo ago | 4 | — | Deadpooled | 37 patents Cardiovascular therapeutics using perhexiline for heart failure and hypertrophic cardiomyopathy | — |
| 12 | Xention Develops ion channel-modulating drugs for the treatment of atrial fibrillation, overactive bladder and… | $19M | 140 mo ago | 13 | Patrick Round Co-Founder | Series D | 139 patents Potassium channel‑blocking antiarrhythmic thieno‑pyrimidine compounds for cardiac therapy | — |
| 13 | Caristo Diagnostics Developer of technology for cardiac disease risk assessment and analysis | $19M | 38 mo ago | 20 | Stefan Neubauer Co-Founder | Series A | 4 patents Radiomic analysis of medical imaging for vascular disease detection and risk assessment | 2 awards |
| 14 | B-Secur Platform offering security and authentication solutions | $18M | 34 mo ago | 70 70 → 37 (-47%) | Alan Foreman Co-Founder & CEO | Series B | 36 patents Wearable biometric monitoring devices for human and animal health diagnostics | 1 launch |
| 15 | Creavo Medical Technologies Digital cardiology health management and monitoring device for providers | $18M | 107 mo ago | 17 | — | Deadpooled | 30 patents Medical magnetometer systems for non‑invasive tissue magnetic field diagnostics. | — |
| 16 | Vascular Flow Developer of Vascular devices based on spiral laminar flow technology | $17M | 89 mo ago | 10 10 → 10 (+0%) | — | Series B | 37 patents Implantable vascular conduits, stents, and grafts for blood‑flow management | — |
| 17 | Deltex Medical A fluid management and cardiac output monitoring system | $14M | 35 mo ago | 46 46 → 39 (-15%) | — | Public | 24 patents Invasive cardiovascular monitoring, combining blood flow and pressure via flexible esophageal Doppler probes | — |
| 18 | Critical Pressure Developer of small molecules for vascular dysfunction and shock | $13M | 103 mo ago | 2 | David Grainger CEO | Deadpooled | — | — |
| 19 | Pathfinder Medical Developer of electronic guidance system used in sugery | $12M | 53 mo ago | 11 11 → 14 (+27%) | — | Series A | — | — |
| 20 | IsomAb Developer of antibodies against vascular diseases | $10M | 28 mo ago | 3 | David Bates Chief Scientific Officer and Founder | Series A | — | — |
| 21 | Echopoint Medical Developer of smart devices for monitoring coronary artery disease and microvascular dysfunction | $10M | 6 mo ago | 8 | Ioannis Papakonstantinou Co-Founder | Series A | — | — |
| 22 | Plaquetec Developer of a method to profile the biology of coronary artery 22Talent top 28%Moat top 39%Product top 41%News top 43% All 10 signals ▾Talenttop 28% Moattop 39% Producttop 41% Newstop 43% Patentstop 45% Fundingtop 49% Techbottom 49% Innovationbottom 47% Globalbottom 42% Marketbottom 15% Talent: Analyst team rating 4/5 Moat: Editorial + unicorn rating 3/10 · IP moat: 44 patents rank vs industry peers · Fliar Intelligence Index 22/100 | $8M | 1 mo ago | 2 | — | Series A | 44 patents Vascular catheter systems for intravascular sampling and biomarker‑based prognosis | — |
| 23 | GEN inCode Developer of precison medicines by combining genetic and clinical data for cardiac disease monitoring | $4M | 30 mo ago | 26 26 → 47 (+81%) | — | Public | — | — |
| 24 | Intelesens Provider of defibrillation and ECG electrodes for vital signs monitoring | $3M | 133 mo ago | 30 | — | Acquired | 14 patents Patents concentrated in health & consumer products | — |
| 25 | Celixir Stem Cell and Regenerative therapy for heart disease | $3M | 99 mo ago | 1 | — | Seed | — | — |
| 26 | Capillary Film Technology Point-of-care test for acute coronary syndrome | $2M | 138 mo ago | 4 | Nuno Reis Co-Founder & Director | Funding Raised | — | — |
| 27 | Metix Medical Provider of a range of multi-parameter patient monitoring solutions | $2M | 108 mo ago | 43 | Julio Enrique Guerrero Ontiveros CEO | Seed | — | — |
| 28 | George Medicines Developer of single-pill combination treatments for cardiometabolic diseases | $2M | 47 mo ago | 2 | Mark Mallon CEO | Seed | — | — |
| 29 | Acrongenomics Lab-on-chip device for point of care molecular diagnostics and drug discovery | $1M | 229 mo ago | — | Platon Tzouvales CEO | Late Stage | — | — |
| 30 | Braidlock Developer of medical catheter and tubing protection device | $1M | 98 mo ago | — | Jeff Smith Chairman & CEO | Seed | 37 patents Medical line securing devices and fasteners for catheters and surgical tubing | — |
| 31 | VascVersa Developer of cell therapies for vascular regeneration | $951K | 46 mo ago | 3 | Christina Neill Founder & CEO | Seed | 2 patents Formulating specialized cell culture media for bioproduction and research applications. | — |
| 32 | Dot Medical Medical equipments for treatment of cardiac conditions | $864K | 166 mo ago | 11 11 → 11 (+0%) | Ian Rankin Founder & MD | Early Stage | — | — |
| 33 | InoCardia Developer of device for cardiac muscle inotropy measurement | $839K | 129 mo ago | 4 | — | Seed | — | — |
| 34 | Newtec Vascular Device for the treatment of hyperplasia | $650K | 94 mo ago | 3 | — | Seed | 10 patents Implantable vascular stents and surgical clips for minimally invasive cardiovascular procedures. | — |
| 35 | Remote Diagnostic Technologies Provider of a suite solution for patient health management | $474K | 198 mo ago | 101 | — | Acqui-Hired | 10 patents Medical telemetry data transmission protocols for remote patient monitoring systems. | — |
| 36 | Renephra Wearable device for controlled fluid removal from skin to treat edema | $467K | 90 mo ago | 1 | — | Seed | 15 patents Microneedle-based transdermal fluid extraction and sampling devices for medical diagnostics | — |
| 37 | SignaCor Developer of therapeutics for cardiac diseases | $334K | 3 mo ago | — | Chris Watson Founder & CEO | Seed | — | — |
| 38 | Olberon Developer of venous access and diagnostic devices | $117K | 96 mo ago | 2 | Arash Bakhtyari Founder & CEO | Funding Raised | 36 patents IV access and needle guidance devices for improved cannulation and fluid management | — |
Top 12 Cardiac and Vascular Disorders companies in United Kingdom
#1
Series D · Cambridge, England · founded 2011 · 45 employees$178.9Mraised▾
Developer of small molecule inhibitors targeting specific disease associated enzymes. These therapeutic candidates focus on the regulation of cellular quality control processes to address neurodegenerative conditions, heart disease, kidney disease, and fibrosis. The research centers on the modulation of protein degradation pathways to influence disease progression.
- Oct 2025Series D$13.3M
- Jul 2024Grant (prize money)$5.2M
- Mar 2024Series D$32.2M
- Jan 2021Series C$3.7M
#2
Series A · Cambridge, England · founded 2008 · 2 employees$8Mraised▾
Developer of a method to profile the biology of coronary artery. It is building cohorts to endotype the disease for the first time. The approach enables the identification of new disease-specific drug targets. This paves the way for precision medicine for patients with coronary artery disease.
- Apr 2026Series A$5M
- Apr 2024Series A$8M
#3
Series A · London, England · founded 2024$411Mraised▾
Developer of oral and injectable peptide therapies for metabolic diseases. Research focuses on creating rationally engineered peptides to address obesity and related cardiometabolic conditions. The pipeline includes oral formulations of GLP-1 analogs and amylin-based candidates designed for once-weekly administration. These therapeutic programs utilize proprietary absorption enhancers to support delivery and manufacturing. The portfolio encompasses both monotherapies and combination treatments aimed at managing weight and metabolic health through various biological mechanisms.
- Jan 2025Series A$411M
#4
Series A · London, England · founded 2018 · 8 employees$9.7Mraised▾
Developer of smart devices for monitoring coronary artery disease and microvascular dysfunction. The company is involved in the development of optical-fiber based sensors that integrate into medical devices for monitoring cardiac helath. It has developed iKOs microcatheter device that uses nanomaterials and sensors that can be positioned into cardiovascular devices for detecting the heart conditions by using iKOR technology.
- Nov 2025Series A$250K
- Mar 2024Series A$5.4M
- Sep 2019Series A$4.4M
- Sep 2019Grant (prize money)—
#5
Series B · Derby, England · founded 2003 · 11 employees$37.6Mraised▾
InterVene is a medical device start-up company developing therapy for severe venous disease in the legs. This technology represents catheter-based, non-implantable approach, which allows physicians to create new vein valves for patients who are unable to efficiently pump blood out of their legs and back to their heart. Its catheter technology is based on a proved open-surgical predicate (Maleti Neovalve) that durably creates new valves out of the patient's native vein wall tissue. This minimally invasive approach allows for access to a new segment of the CVI market by transitioning that strategy of care away from costly, chronic, disease management to curative intervention
- Oct 2024Series B$13M
- Mar 2023Series B$1.5M
- Jun 2019Series B$15M
- Jun 2017Series A$2.2M
#6
Seed · Belfast, Northern Ireland · founded 2024$333.9Kraised▾
Developer of therapeutics for cardiac diseases. It offers a patented low-dose 5-aza therapy that harnesses DNA methylation to address multiple underlying causes of symptomatic hypertrophic cardiomyopathy including established fibrosis a key driver of disease progression.
- Mar 2026Seed$333.9K
#7
Series B · Belfast, Northern Ireland · founded 2014 · 70 employees$18.2Mraised▾
Platform offering security and authentication solutions. It provides tools to help organizations verify identities, manage access, and protect sensitive data. The platform supports workflows related to safeguarding user information and ensuring secure authentication processes.
- Jul 2023Series B—
- Nov 2021Series B$3M
- Sep 2020Series A$1.9M
- May 2020Series A$2.2M
#8
Series A · Nottingham, England · founded 2022 · 3 employees$10.5Mraised▾
Developer of antibodies against vascular diseases. It is developing isoform-specific, humanized IgG1-based antibodies using a combined bioinformatics-based platform against Vascular Endothelial Growth Factor A (VEGF-A).
- Feb 2024Series A$9.5M
- Dec 2022Seed$1M
#9
Public · Chichester, England · founded 1992 · 46 employees$13.6Mraised▾
Deltex Medical develops fluid management devices. CardioQ-ODM+ is a fluid management and cardiac output monitoring system to measure both flow and pressure. It is designed for intensive care and high risk surgical application. It brings together oesophageal doppler monitoring flow based technology with pulse pressure waveform system.
- Jul 2023Post IPO$2.4M
- Feb 2018Post IPO$4M
- Nov 2017Grant (prize money)$59.3K
- Jun 2017Grant (prize money)$59.5K
#10
Series A · Oxford, England · founded 2017 · 20 employees$18.9Mraised▾
Developer of technology for cardiac disease risk assessment and analysis. The company provides tools for preventive screening, disease diagnosis, and intervention planning. It supports drug clinical trials and clinical research. The technology analyzes inflammation related to cardiac issues.
- Apr 2023Series A$16.3M
- Mar 2021Series A—
- Mar 2021Grant (prize money)$639.7K
- Oct 2018Seed$2.6M
#11
Series B · Swansea, Wales · founded 2007 · 21 employees$24.4Mraised▾
Developer of implantable heart pumps for heart failure treatment. It offers a miniaturized ventricular assist device MiniVAD system that consists of an implanted pump and peripheral devices to improve the function of a failing heart ventricle. The technology aims to address the significant unmet need in treating chronic heart failure. The device consists of an implanted pump and external components working together as a circulatory support system.
- Feb 2022Series B$9M
- Nov 2020Series B$13.3K
- Sep 2019Series B$145.1K
- Jan 2018Series B$2.9M
#12
Public · Manchester, England · founded 2018 · 26 employees$4.5Mraised▾
GEN inCode is a developer of precision medicines by combining genetic and clinical data for cardiac disease monitoring. It provides solutions for the prevention and treatment of cardiovascular disease risk. The models are based on algorithms and machine learning which allows doctors to accurately measure and assess a patient's clinical and genetic risk.
- Dec 2023Post IPO$5.1M
- Aug 2021Post IPO$694.9K
- Jul 2020Series A$4.5M
- Jan 2020Seed$982.1K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Cardiac and Vascular Disorders coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding flat · growth rising
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.